Talking Points

Bölümler

• 
  The FAME 3 Trial 16.09.2026 9dk

  William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
• 
  The TRILUMINATE Pivotal Trial 02.09.2026 8dk

  Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
• 
  The PRAGUE-25 Study 05.08.2026 7dk

  Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
• 
  The BETAMI-DANBLOCK Trial 22.07.2026 8dk

  How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
• 
  New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI 01.07.2026 1sa 33dk

  In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
• 
  The PROCTOR Trial 03.06.2026 8dk

  Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
• 
  The SELUTION DeNovo Trial 20.05.2026 5dk

  Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
• 
  The VESALIUS-CV Trial 06.05.2026 7dk

  Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
• 
  The META-AF Trial 22.04.2026 4dk

  Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
• 
  Evolution of Pharmacotherapy in STEMI 01.04.2026 8dk

  How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
• 
  The CorCMR Trial 04.03.2026 5dk

  Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
• 
  The TUXEDO-2 Trial 04.02.2026 3dk

  Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
• 
  The FLOW Trial 07.01.2026 5dk

  C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
• 
  The 2024 ESC CCS Guidelines 17.12.2025 15dk

  Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
• 
  The My Heart Your Heart Trial 10.12.2025 6dk

  Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
• 
  The FAVOR III Europe Trial 03.12.2025 14dk

  Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
• 
  The FLOW Trial 03.12.2025 5dk

  C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
• 
  STORM-PE TRIAL 19.11.2025 14dk

  James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
• 
  The EARLY TAVR and TAVR UNLOAD Trials 12.11.2025 15dk

  For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
• 
  The EPIC-CAD Trial 29.10.2025 14dk

  Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.